Chardan Capital maintains Buy rating on Adagene, $9 price target

Chardan Capital kept a Buy rating and $9 price target on Adagene, implying 248.8% upside from the Oct 27 close. The firm cited Adagene's strong immunotherapy pipeline, including ADG126 in clinical trials, and its advanced antibody design technologies.

Original reporting
Published Oct 28, 2026, 12:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 12:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Chardan Capital maintains Buy rating on Adagene, $9 price target — source image
Decision brief

The 30-second read

Med
01

Why it matters

The analyst's price target suggests significant upside but hinges on trial success.

02

Market read

Analyst rating may drive short-term buying pressure in ADGE.

03

What to watch

Potential regulatory or trial setbacks could limit upside.

Relevance 5/10Novelty 5/10Timing: today

Background

Adagene is a clinical-stage biotech developing immunotherapy candidates, with ADG126 in early-phase trials.

Market effects

Highlights continued optimism in biotech small-caps and may influence peer valuations.

Limited to US biotech investors; no broader market effect.

Minimal global impact beyond niche biotech community.

Counterpoint

The high target may be overly optimistic given early-stage trial status.

Key entities

  • Adagene

    Biotech firm developing immunotherapy candidates.

  • Chardan Capital

    Equity research firm issuing the rating.

Related articles

$ADAGLowAI 8/10

Adagene completes enrollment in phase 2 trial of muzastotug

Adagene Inc. (ADAG) completed enrollment in a Phase 2 trial of muzastotug, an anti-CTLA-4 antibody therapy, combined with Merck’s KEYTRUDA for late-line colorectal cancer. The trial enrolled 60 patients, with results expected in early 2027. The FDA confirmed Phase 3 trial design elements, and Sanofi invested in the trial. Muzastotug has FDA Fast Track designation.